XTalks
APRIL 1, 2025
Equillium announced encouraging topline results from its Phase III EQUATOR study evaluating itolizumab in combination with corticosteroids as a first-line treatment for patients with acute graft-versus-host disease (aGVHD). The randomized, double-blind, placebo-controlled global trial assessed itolizumab in patients with newly diagnosed grade II-IV aGVHD.
Bio Pharma Dive
APRIL 1, 2025
Reduction-in-force notices went out Tuesday morning to employees across HHS. At FDA, OND director Peter Stein is departing as cuts hit CDER.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
APRIL 1, 2025
The FDA has approved Sanofis Qfitlia (fitusiran), making it the first approved siRNA therapy for hemophilia A or B, and the first for the conditions with or without inhibitors. It is indicated to prevent or reduce bleeding episodes in patients aged 12 and older, with or without factor VIII or IX inhibitors. Qfitlia is also the first antithrombin-lowering therapy approved for routine prophylaxis in hemophilia A or B.
Bio Pharma Dive
APRIL 1, 2025
Airna will use the Series B round to launch a Phase 1/2 trial of its lead program for alpha-1 antitrypsin deficiency, a disease targeted by several other firms.
Speaker: Simran Kaur, Co-founder & CEO at Tattva.Health
AI is transforming clinical trials—accelerating drug discovery, optimizing patient recruitment, and improving data analysis. But its impact goes far beyond research. As AI-driven innovation reshapes the clinical trial process, it’s also influencing broader healthcare trends, from personalized medicine to patient outcomes. Join this new webinar featuring Simran Kaur for an insightful discussion on what all of this means for the future of healthcare!
Pharmaceutical Technology
APRIL 1, 2025
Total deal value of innovator drug licensing agreements involving Chinese biopharma licensors has risen 66% to $41.5 billion in 2024.
Bio Pharma Dive
APRIL 1, 2025
A Texas judge vacated the FDA’s final rule, which was strongly opposed by the laboratory industry, and remanded the matter to HHS Secretary Robert F. Kennedy Jr.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
pharmaphorum
APRIL 1, 2025
Reduction in force (RIF) job losses have started in earnest at US federal agencies, including the FDA and CDC, according to media reports
Pharmaceutical Technology
APRIL 1, 2025
Is 'nearshoring', the preference among pharma and biotech to move operations to the domestic markets versus outsourcing abroad, becoming the norm?
pharmaphorum
APRIL 1, 2025
EVERSANA has joined the growing roster of companies partnering with Veeva on the development of GenAI applications for the life sciences industry
Pharmaceutical Technology
APRIL 1, 2025
In 2025, the CNS market is forecast to surpass $80bn in sales for the first time since 2013, marking a significant turnaround.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
APRIL 1, 2025
The UK has given a world-first approval to Rotop's RoTecPSMA, a new imaging agent for detecting lesions in men with prostate cancer
Pharmaceutical Technology
APRIL 1, 2025
BioVersys has announced the grant of key patent claims in China for the BV100 technology, the intravenous formulation of rifabutin.
Pharma Times
APRIL 1, 2025
Collaboration expands AI-based risk profiling tools
Pharmaceutical Technology
APRIL 1, 2025
Platform trials offer increased flexibility and reduced costs for sponsors and CROs in clinical studies.
pharmaphorum
APRIL 1, 2025
AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780 as it tries to narrow a lead held by MSD with its rival cholesterol drug
Pharmaceutical Technology
APRIL 1, 2025
US-based Johnson & Johnson (J&J) has announced that it will be investing $55bn in new US manufacturing facilities over the next four years.
Pharmaceutical Commerce
APRIL 1, 2025
In the first part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Colin Banas, MD, DrFirsts chief medical officer, discusses the challenges that many Americans face regarding the affordability of GLP-1 drugs.
Pharmaceutical Technology
APRIL 1, 2025
A federal judge in Houston has rejected the third attempt by J&J subsidiary Red River to settle lawsuits related to its talc-based products.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Commerce
APRIL 1, 2025
The latest news for pharma industry insiders.
Pharmaceutical Technology
APRIL 1, 2025
Abrysvo is now approved in the EU for adults aged 18 to 59 who are at increased risk of lower respiratory tract disease caused by RSV.
pharmaphorum
APRIL 1, 2025
PM Society announces the launch of The PMi Awards 2025 Sara.
Pharmaceutical Technology
APRIL 1, 2025
With an increasing demand for NHS services, technology is being positioned as a critical tool in eliminating inefficiencies and delays. The UK governments latest strategy prioritises AI-driven decision-making, advanced data-sharing mechanisms, and the integration of digital platforms to ensure seamless patient care.
pharmaphorum
APRIL 1, 2025
The UK's NHS is poised for a grand resurgence in commercial clinical trials, offering significant opportunities for medical research and innovation. Learn more about the exciting potential for collaboration.
Pharmaceutical Technology
APRIL 1, 2025
The formulation allows for greater stockpiling, with Bavarian Nordic already working with the US government to add to vaccine reserves.
pharmaphorum
APRIL 1, 2025
ISPE Singapore Affiliate Conference & Exhibition 2025 Sara.
Pharmaceutical Technology
APRIL 1, 2025
Apollomics and LaunXP have signed an agreement to develop and commercialise the formers c-Met inhibitor vebreltinib.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 1, 2025
The Parliamentary Panel on Health and Family Welfare has recommended to the Ministry of Ayush to approach the Ministry of Finance and seek higher budgetary allocation at the supplementary demand stage to ensure that no undertaken project or scheme gets suffered for want of requisite funds.
Pharmaceutical Technology
APRIL 1, 2025
The establishment of NHS England (NHSE) to undertake functions previously the responsibility of the then Department of Health (now DHSC) took place 13 years ago, following the enactment of the Health and Social Care Act 2012 - primarily the result of policies of the secretary of state for health at the time,Andrew Lansley.
AuroBlog - Aurous Healthcare Clinical Trials blog
APRIL 1, 2025
(Yulia-Images/Getty Images) One of the most consumed drugs in the US and the most commonly taken analgesic worldwide may do a lot more than simply take the edge off your headache.
Pharmaceutical Technology
APRIL 1, 2025
NorthWest EHealth is a winner in the Innovation, Safety, and Diversity categories in the 2025 Pharmaceutical Excellence Awards.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Expert insights. Personalized for you.
94 
Let's personalize your content